When it comes to efficient distribution of the COVID-19 vaccine and other drugs, the pharmaceutical supply chain is falling short.
The fearsome scale of the coronavirus pandemic would pose a challenge for the world’s most efficient pharma supply chain. After all, there are numerous factors beyond the control of drug manufacturers and distributors, including political hurdles, carrier and warehouse capacity constraints, and geographic complications. Still, the industry’s supply chain has a lot of structural drawbacks to answer for, not least of which is a lack of end-to-end visibility. In this episode, we look into the problem with Roddy Martin, chief digital transformation officer with TraceLink, Inc. He explains why pharma can’t maintain an agile, reliable and efficient supply chain without the cushion of excess inventory. And he prescribes what the industry must do now to rectify its shortcomings, at a time when distribution failures can have fatal consequences for the patient population. Hosted by Bob Bowman, Editor-in-Chief of SupplyChainBrain.
Show notes:
A white paper from IDC and TraceLink on “Supply Chain Agility in the Pharmaceutical Industry.”
